Live Nasdaq Composite: Stocks Sink on Worrisome Q2 Tech Earnings, Oil Retakes $100

Investing

Merck : MRK

All Merck Articles

1089 Articles

Douglas A. McIntyre | Feb 28, 2012 at 6:11 PM EST

FDA-Use Of Statins May Cause Problems

The FDA announced today that the use of statins, common among people with high cholesterol, pose problems which were not…

Jon C. Ogg | Feb 13, 2012 at 4:17 PM EST

Drug & Biotech Makers Respond Unfavorably To Obama Budget Proposals (AMGN, BIIB, BMY, GSK, JNJ, MRK, PFE)

The Pharmaceutical Research and Manufacturers of America (PhRMA) has spoken out against the new 2013 budget proposed by President Obama. …

Paul Ausick | Feb 6, 2012 at 2:54 PM EST

Merck Will Seek FDA Approval for Insomnia Drug (MRK)

Drug giant Merck & Co. (NYSE: MRK) plans to file this year with the US FDA for approval of the…

Paul Ausick | Feb 2, 2012 at 4:08 PM EST

24/7 Wall St. Closing Bell (DELL, EW, AKS, STLD, BRCM, GMCR, EDMC, NDAQ, QCOM, BZH, BSX, BCO, DO, LEA, MRK, TTWO, VIAB, ZNGA, MNOV, RGDX, BIOS, URG)

All three major US stock indexes opened higher this morning, and spent the rest of the day bouncing around the…

Jon C. Ogg | Feb 2, 2012 at 8:55 AM EST

Merck Close to 52-Week High After Earnings (MRK)

Merck & Company, Inc. (NYSE: MRK) is trading up after its earnings report. With a high dividend yield of 4.4%,…

Jon C. Ogg | Feb 1, 2012 at 3:43 PM EST

Top Earnings Previews For Thursday (BZH, PHM, BX, CME, DOW, GNW, GILD, IP, K, MA, MRK, RCL, HOT, TRMB, VRTX, YRCW)

Earnings season is still upon us. There are going to be many big earnings reports Thursday and we would consider…

Jon C. Ogg | Jan 31, 2012 at 7:17 AM EST

Pfizer Sneaks By Earnings Estimates (PFE, MRK)

Pfizer, Inc. (NYSE: PFE) looks good on the surface on its earnings report for the fourth quarter, but the company’s…

Jon C. Ogg | Jan 23, 2012 at 6:33 PM EST

Cramer Now Touts Merck For Drug & Yield (MRK, PFE)

Jim Cramer has touted several DJIA upside calls in 2012, but on Monday’s MAD MONEY on CNBC Cramer touted Merck…

Paul Ausick | Jan 11, 2012 at 1:37 PM EST

Pharma Value Beyond The Patent Expiration Cliff (PFE, MRK, BMY, TEVA, AMGN, GSK)

The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking…

Jon C. Ogg | Jan 10, 2012 at 3:47 PM EST

Achillion Pharma, Too Much of a Good Thing After 50% Gain? (ACHN, MRK, GILD, VRUS, BMY, INHX, VRTX)

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) has been on fire due to the rapid interest of hepatitis C treatments and the bidding of…

Paul Ausick | Jan 9, 2012 at 4:07 PM EST

24/7 Wall St. Closing Bell (COST, XOM, AKAM, P, SCCO, MRK, AYI, CBST, AA, INHX, PSOF, IDIX, NFLX, THRX, LTRX)

US markets opened up slightly this morning and have maintained a slight positive tone for most of the day. Today…

Jon C. Ogg | Jan 9, 2012 at 8:09 AM EST

Top Analyst Upgrades & Downgrades (AKAM, GAS, AAPL, ARMH, B, COST, XOM, FR, HTH, IART, IGT, MRK, P, PENN, PVH, RBS, SCCO, THOR)

Jon OggThese are some of the top analyst upgrades, downgrades, and initiations seen from Wall Street brokerage and research firms…

Jon C. Ogg | Jan 4, 2012 at 8:01 AM EST

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

For several years it has been the case that Amgen Inc. (NASDAQ: AMGN) was considered a biotech though it had at…

Jon C. Ogg | Jan 3, 2012 at 6:40 AM EST

DJIA 2012: Best Targets Imply DJIA 13,678 (BAC, JPM, VZ, IBM, CVX, MCD, CSCO, XOM, GE, HPQ, INTC, MRK, PFE, PG, WMT, DIA)

As each new year replaces the prior year, 24/7 Wall St. looks at the individual targets on all 30 Dow…

Jon C. Ogg | Dec 29, 2011 at 1:02 PM EST

Which Dogs of the Dow Are Best in 2012? (T, VZ, MRK, PFE, GE, DD, JNJ, INTC, PG, MSFT, CVX, JPM, KFT, MCD)

The lineup of the Dogs of the Dow, simply the ten highest dividend yield stocks of the thirty Dow Jones…

1 … 58 59 60 61 62 … 73

Merck : MRK

All Merck Articles

FDA-Use Of Statins May Cause Problems

Drug & Biotech Makers Respond Unfavorably To Obama Budget Proposals (AMGN, BIIB, BMY, GSK, JNJ, MRK, PFE)

Merck Will Seek FDA Approval for Insomnia Drug (MRK)

24/7 Wall St. Closing Bell (DELL, EW, AKS, STLD, BRCM, GMCR, EDMC, NDAQ, QCOM, BZH, BSX, BCO, DO, LEA, MRK, TTWO, VIAB, ZNGA, MNOV, RGDX, BIOS, URG)

Merck Close to 52-Week High After Earnings (MRK)

Top Earnings Previews For Thursday (BZH, PHM, BX, CME, DOW, GNW, GILD, IP, K, MA, MRK, RCL, HOT, TRMB, VRTX, YRCW)

Pfizer Sneaks By Earnings Estimates (PFE, MRK)

Cramer Now Touts Merck For Drug & Yield (MRK, PFE)

Pharma Value Beyond The Patent Expiration Cliff (PFE, MRK, BMY, TEVA, AMGN, GSK)

Achillion Pharma, Too Much of a Good Thing After 50% Gain? (ACHN, MRK, GILD, VRUS, BMY, INHX, VRTX)

24/7 Wall St. Closing Bell (COST, XOM, AKAM, P, SCCO, MRK, AYI, CBST, AA, INHX, PSOF, IDIX, NFLX, THRX, LTRX)

Top Analyst Upgrades & Downgrades (AKAM, GAS, AAPL, ARMH, B, COST, XOM, FR, HTH, IART, IGT, MRK, P, PENN, PVH, RBS, SCCO, THOR)

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

DJIA 2012: Best Targets Imply DJIA 13,678 (BAC, JPM, VZ, IBM, CVX, MCD, CSCO, XOM, GE, HPQ, INTC, MRK, PFE, PG, WMT, DIA)

Which Dogs of the Dow Are Best in 2012? (T, VZ, MRK, PFE, GE, DD, JNJ, INTC, PG, MSFT, CVX, JPM, KFT, MCD)

Live Nasdaq Composite: Stocks Sink on Worrisome Q2 Tech Earnings, Oil Retakes $100

Live: Will Decker Brands Beat Q1 Earnings Tonight After the Market Closes?

Live: Can Intel Continue Its Meteoric 327% Run With Q2 Earnings Tonight?

HDV Delivers 3.1% Yield While Beating SPY Year to Date by 9 Points

A Chinese CEO Just Outlined the Bear Case for NVIDIA. It Should Terrify Owners of the Stock.

Retirees Chasing 21% Returns Should Know SVOL’s True Cost

The Helicopter Is the Fastest Way to the ER. The 20% Medicare Leaves Behind Is the Priciest Part of the Ride.

Why Pulling From Your IRA Before Your Taxable Account Still Costs Retirees Five Figures, Even With No Penalty

Established Firm Harding Loevner Enters ETF Market With LOEV for International Investors

HDV Delivers 3.1% Yield While Beating SPY Year to Date by 9 Points

Merck : MRK

All Merck Articles

FDA-Use Of Statins May Cause Problems

Drug & Biotech Makers Respond Unfavorably To Obama Budget Proposals (AMGN, BIIB, BMY, GSK, JNJ, MRK, PFE)

Merck Will Seek FDA Approval for Insomnia Drug (MRK)

24/7 Wall St. Closing Bell (DELL, EW, AKS, STLD, BRCM, GMCR, EDMC, NDAQ, QCOM, BZH, BSX, BCO, DO, LEA, MRK, TTWO, VIAB, ZNGA, MNOV, RGDX, BIOS, URG)

Merck Close to 52-Week High After Earnings (MRK)

Top Earnings Previews For Thursday (BZH, PHM, BX, CME, DOW, GNW, GILD, IP, K, MA, MRK, RCL, HOT, TRMB, VRTX, YRCW)

Pfizer Sneaks By Earnings Estimates (PFE, MRK)

Cramer Now Touts Merck For Drug & Yield (MRK, PFE)

Pharma Value Beyond The Patent Expiration Cliff (PFE, MRK, BMY, TEVA, AMGN, GSK)

Achillion Pharma, Too Much of a Good Thing After 50% Gain? (ACHN, MRK, GILD, VRUS, BMY, INHX, VRTX)

24/7 Wall St. Closing Bell (COST, XOM, AKAM, P, SCCO, MRK, AYI, CBST, AA, INHX, PSOF, IDIX, NFLX, THRX, LTRX)

Top Analyst Upgrades & Downgrades (AKAM, GAS, AAPL, ARMH, B, COST, XOM, FR, HTH, IART, IGT, MRK, P, PENN, PVH, RBS, SCCO, THOR)

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

DJIA 2012: Best Targets Imply DJIA 13,678 (BAC, JPM, VZ, IBM, CVX, MCD, CSCO, XOM, GE, HPQ, INTC, MRK, PFE, PG, WMT, DIA)

Which Dogs of the Dow Are Best in 2012? (T, VZ, MRK, PFE, GE, DD, JNJ, INTC, PG, MSFT, CVX, JPM, KFT, MCD)

Live Nasdaq Composite: Stocks Sink on Worrisome Q2 Tech Earnings, Oil Retakes $100

Live: Will Decker Brands Beat Q1 Earnings Tonight After the Market Closes?

Live: Can Intel Continue Its Meteoric 327% Run With Q2 Earnings Tonight?

HDV Delivers 3.1% Yield While Beating SPY Year to Date by 9 Points

A Chinese CEO Just Outlined the Bear Case for NVIDIA. It Should Terrify Owners of the Stock.

Retirees Chasing 21% Returns Should Know SVOL’s True Cost

Featured Reads

The Helicopter Is the Fastest Way to the ER. The 20% Medicare Leaves Behind Is the Priciest Part of the Ride.

Why Pulling From Your IRA Before Your Taxable Account Still Costs Retirees Five Figures, Even With No Penalty